MRNA is trading 4% up at $72.84, extending a significant rally fueled by multiple catalysts. Investors are responding to recent positive regulatory momentum for its flu vaccine, mFlusiva, as well as bullish messaging from its Science Day regarding a diversified mRNA pipeline in oncology and autoimmune diseases. A likely short-covering component has also contributed to the stock's sharp upward movement.